Otsuka (OTCMKTS:OTSKY) Shares Gap Up – Here’s Why

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) gapped up prior to trading on Tuesday . The stock had previously closed at $31.85, but opened at $33.15. Otsuka shares last traded at $33.2362, with a volume of 3,518 shares trading hands.

Analyst Upgrades and Downgrades

OTSKY has been the subject of several research analyst reports. Zacks Research upgraded shares of Otsuka from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 31st. The Goldman Sachs Group downgraded shares of Otsuka from a “strong-buy” rating to a “strong sell” rating in a research note on Friday, February 27th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Otsuka presently has a consensus rating of “Hold”.

Otsuka Stock Down 1.4%

The company has a debt-to-equity ratio of 0.05, a current ratio of 2.17 and a quick ratio of 1.67. The company has a market cap of $35.35 billion and a price-to-earnings ratio of 13.89. The firm’s 50 day simple moving average is $34.51 and its 200-day simple moving average is $32.40.

Otsuka (OTCMKTS:OTSKY) last released its quarterly earnings data on Tuesday, April 28th. The company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.16. Otsuka had a net margin of 15.01% and a return on equity of 12.33%. The company had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. As a group, sell-side analysts anticipate that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.98 earnings per share for the current year.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.